Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 13/20 | 0.64 |
| ▸ | MMP2 | P08253 | 13/20 | 0.64 |
| ▸ | MMP9 | P14780 | 13/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199523 | 1.00 | MMP1 (0.64) | MMP1MMP2MMP9MEN1AKR1B1 | |
| SCHEMBL29403984 | 1.00 | MMP1 (0.64) | MMP1MMP2MMP9MEN1AKR1B1 | |
| SCHEMBL30041332 | 1.00 | MMP1 (0.64) | MMP1MMP2MMP9MEN1AKR1B1 | |
| SCHEMBL9973849 | 0.91 | MMP1 (0.63) | MMP1MMP2MMP9MEN1AKR1B1 | |
| SCHEMBL30492916 | 0.90 | MMP1 (0.58) | MMP1MMP2MMP9MEN1AKR1B1 | |
| SCHEMBL10005257 | 0.89 | MMP1 (0.66) | MMP1MMP2MMP9MEN1AKR1B1 | |
| SCHEMBL29913807 | 0.89 | TRPM2 (0.62) | MMP1MMP2MMP9MEN1KMT2A | |
| SCHEMBL4670083 | 0.89 | TRPM2 (0.62) | MMP1MMP2MMP9MEN1KMT2A | |
| SCHEMBL5351229 | 0.89 | TRPM2 (0.62) | MMP1MMP2MMP9MEN1KMT2A | |
| SCHEMBL14227304 | 0.88 | BACE1 (0.56) | MMP1MMP2MMP9MEN1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023140435-A1 | METHOD FOR SYNTHESIZING AVENANTHRAMIDES C | 동아대학교 산학협력단 | 2023-07-27 | — | — | WO | disclosed |
| EP-4114350-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE WITH IMPROVED SKIN PENETRATION | Symrise AG (DE) | 2023-01-11 | — | — | EP | disclosed |
| WO-2021176074-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE WITH IMPROVED SKIN PENETRATION | SYMRISE AG (DE) | 2021-09-10 | — | — | WO | disclosed |
| US-20090124669-A1 | Structural Analogues of Avenanthramides, Their Use in Compositions Useful in the Treatment of Dermatological Disorders | RELIVIA S.R.L | 2009-05-14 | — | — | US | disclosed |
| EP-1856030-A2 | STRUCTURAL ANALOGUES OF AVENANTHRAMIDES, THEIR USE IN COMPOSITIONS USEFUL IN THE TREATMENT OF DERMATOLOGICAL DISORDERS | RELIVIA SRL (IT) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006087393-A2 | STRUCTURAL ANALOGUES OF AVENANTHRAMIDES, THEIR USE IN COMPOSITIONS USEFUL IN THE TREATMENT OF DERMATOLOGICAL DISORDERS | RELIVIA S.R.L. (IT) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124669-A1 | Structural Analogues of Avenanthramides, Their Use in Compositions Useful in the Treatment of Dermatological Disorders | OAT, HLA-DRB1, CUTA | MMP1 165/4885MMP2 1649/4885MMP9 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.